Natalizumab discontinuation and disease restart in pregnancy: A case series

Acta Neurologica Scandinavica

Volumn 131, Issue 5, 2015, Pages 336-340

  De Giglio, L ^a   Gasperini, C ^b   Tortorella, C ^c   Trojano, M ^c   Pozzilli, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SCamillo Forlanini General Hospital   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

Multiple sclerosis; Natalizumab; Pregnancy

Indexed keywords

BETAMETHASONE; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ATAXIA; ATAXIC GAIT; BLURRED VISION; CASE REPORT; DISEASE ACTIVITY; DISEASE RESTART; DRUG WITHDRAWAL; DYSARTHRIA; DYSPHAGIA; EXPANDED DISABILITY STATUS SCALE; FACIAL NERVE PARALYSIS; FEMALE; HUMAN; HYPESTHESIA; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PARESTHESIA; PREGNANCY; PREGNANT WOMAN; QUADRIPLEGIA; RELAPSE; TACTILE HYPOESTHESIA; TRUNCAL ATAXIA; URGE INCONTINENCE; URINARY HESITANCY; URINARY URGENCY; WALKING DIFFICULTY; DRUG EFFECTS; PREGNANCY COMPLICATIONS; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE;

EID: 84926416500     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12364     Document Type: Article

References (13)

1. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
2. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Post-withdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2008; 70(13Pt 2): 1150-1.
3. O'Connor PW, Goodman AD, Kappos L et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858-65.
4. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2011;68:186-91.
5. Martinelli V, Colombo B, Dalla Costa G et al. Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning. Mult Scler 2013 Jun 17. PMID:23773984.
6. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339:285-91.
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
8. Fox R, Cree BA, De Seze J et al. MS disease activity in Restore: a randomized 24-week natalizumab treatment interruption study. Neurology 2014;82:1491-8.
9. Vukusic S, Hutchinson M, Hours M et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004;127(Pt 6):1353-60.
10. Havla J, Kleiter I, Kümpfel T. Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? Ther Clin Risk Manag 2013;9:361-9.
11. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler 2011;17:958-63.
12. Schneider H, Weber CE, Hellwig K, Schroten H, Tenenbaum T. Natalizumab treatment during pregnancy - effects on the neonatal immune system. Acta Neurol Scand 2013; 127: e1-4.
13. Haghikia A, Langer-Gould A, Rellensmann G et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014;71:891-5.